LXRX
Lexicon Pharmaceuticals, Inc.
There isn't enough reported data to score LXRX yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
LXRX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
LXRX's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
LXRX PE Valuation
LXRX has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
LXRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect LXRX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
LXRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.14 | +$0.04 |
| Q2 2026 | -$0.15 | +$0.17 |
| Q1 2026 | -$0.07 | +$0.43 |
| Q4 2025 | -$0.14 | +$0.49 |
| Q3 2025 | -$0.18 | +$0.57 |
| Q2 2025 | -$0.32 | +$0.46 |
| Q1 2025 | -$0.50 | +$0.33 |
| Q4 2024 | -$0.63 | +$0.17 |
LXRX is still losing money, but far less than before: $0.14 per share over the past year, against $1.05 at its worst in late 2020.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over LXRX on earnings quality, reporting a profit while its opponent remains loss making.
LXRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.3M | -21% |
| Q2 2026 | $692K | -98% |
| Q1 2026 | $21.1M | +1572% |
| Q4 2025 | $5.5M | -79% |
| Q3 2025 | $14.2M | +710% |
| Q2 2025 | $28.9M | +1653% |
| Q1 2025 | $1.3M | +12% |
| Q4 2024 | $26.6M | +3683% |
LXRX's revenue has slid since its 2025 peak: $11M last quarter, down 21% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -129% | -43 points |
| Q2 2026 | -3835% | -3848 points |
| Q1 2026 | -4.7% | +2030 points |
| Q4 2025 | -269% | -146 points |
| Q3 2025 | -86% | +3554 points |
| Q2 2025 | 13% | +3374 points |
| Q1 2025 | -2035% | +1977 points |
| Q4 2024 | -123% | +6534 points |
LXRX's operating margin was −129% last quarter, down 43 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over LXRX on profitability, with a higher operating margin.
LXRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.1M | +$15.8M |
| Q1 2026 | -$14.7M | +$29M |
| Q4 2025 | -$17.2M | +$4.7M |
| Q3 2025 | -$23.8M | +$30.1M |
| Q1 2025 | -$43.8M | +$11.4M |
| Q4 2024 | -$22M | +$28.6M |
| Q3 2024 | -$53.9M | -$12.2M |
| Q2 2024 | -$48.8M | -$10.5M |
LXRX has burned cash in almost every quarter: −$49M over the past year, against −$144M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over LXRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
LXRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +7.3M shares |
| 1 year | +22% | +81.6M shares |
| 3 years | +82% | +200M shares |
| 5 years | +205% | +299M shares |
| Available history | +319% | +339M shares |
LXRX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | $1.7M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $824,000 |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LXRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2021 | -1.8x | Net Cash |
| Q1 2020 | 1.9x | Healthy |
| Q4 2019 | 1.4x | Healthy |
LXRX has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
LXRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.4 | Neutral |
| Stochastic | 27.1 | Neutral |
LXRX's weekly RSI is 48 (neutral) and its Stochastic is 27 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
LXRX PE vs Healthcare Sector
| Metric | LXRX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
LXRX has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
LXRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.66 | 9.6% above |
| 20 week MA | $2.02 | 9.9% below |
| 50 week MA | $1.79 | 1.7% above |
| 100 week MA | $1.36 | 34% above |
| 200 week MA | $1.61 | 13% above |
LXRX's trend is mixed: it's above four of its five weekly moving averages, and 13% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over LXRX on trend strength, trading above more of its moving averages.
LXRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.26 | $3.49 | -18% |
| 2021 | $3.49 | $4.36 | +25% |
| 2022 | $4.36 | $1.95 | -55% |
| 2023 | $1.95 | $1.53 | -22% |
| 2024 | $1.53 | $0.77 | -50% |
| 2025 | $0.77 | $1.23 | +60% |
| 2026 YTD | $1.23 | $1.82 | +48% |
LXRX is up 48% so far in 2026, after finishing lower in four of the previous six years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over LXRX on returns for 2026, with the stronger performance.